A novel HER2 targeting nanoagent self-assembled from affibody-epothilone B conjugate for cancer therapy.
Affibody
Drug delivery
Epothilone B
Self-assemble
Targeted cancer therapy
Journal
Journal of nanobiotechnology
ISSN: 1477-3155
Titre abrégé: J Nanobiotechnology
Pays: England
ID NLM: 101152208
Informations de publication
Date de publication:
21 Aug 2024
21 Aug 2024
Historique:
received:
13
06
2024
accepted:
05
08
2024
medline:
22
8
2024
pubmed:
22
8
2024
entrez:
21
8
2024
Statut:
epublish
Résumé
Epothilone B (Epo B), a promising antitumor compound effective against various types of cancer cells in vitro. However, its poor selectivity for tumor cells and inadequate therapeutic windows significantly limit its potential clinical application. Affibody is a class of non-immunoglobulin affinity proteins with precise targeting capability to overexpressed molecular receptors on cancer cells, has been intensively investigated due to its exceptional affinity properties. In this study, we present a targeted nanoagent self-assembled from the precursor of an affibody conjugated with Epo B via a linker containing the thioketal (tk) group that is sensitive to reactive oxygen species (ROS). The core-shell structure of the Z
Identifiants
pubmed: 39169343
doi: 10.1186/s12951-024-02754-4
pii: 10.1186/s12951-024-02754-4
doi:
Substances chimiques
Receptor, ErbB-2
EC 2.7.10.1
Epothilones
0
Recombinant Fusion Proteins
0
epothilone B
UEC0H0URSE
Antineoplastic Agents
0
ERBB2 protein, human
EC 2.7.10.1
Reactive Oxygen Species
0
affibody (ZHER2-342)2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
502Subventions
Organisme : National Natural Science Foundation of China
ID : 22201178
Organisme : National Natural Science Foundation of China
ID : 52273281
Informations de copyright
© 2024. The Author(s).
Références
Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995;55:2325–33.
pubmed: 7757983
Höfle G, Bedorf N, Steinmetz H, Schomburg D, Gerth K, Reichenbach H. Epothilone A and B—novel 16-membered macrolides with cytotoxic activity: isolation, crystal structure, and conformation in solution. Angew Chem Int Ed. 1996;35:1567–9.
Nicolaou KC, Rhoades D, Wang Y, Bai R, Hamel E, Aujay M, et al. 12, 13-Aziridinyl epothilones. Stereoselective synthesis of trisubstituted olefinic bonds from methyl ketones and heteroaromatic phosphonates and design, synthesis, and biological evaluation of potent antitumor agents. J Am Chem Soc. 2017;139:7318–34.
pubmed: 28513142
Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B, et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA. 2000;97:2904–9.
pubmed: 10688884
pmcid: 16028
Zhang P, Zhang L, Jiang X, Diao XT, Li S, Li DD. Docking-guided rational engineering of a macrolide glycosyltransferase glycodiversifies epothilone B. Commun Biol. 2022;5:100.
pubmed: 35087210
pmcid: 8795383
Chiorazzi A, Nicolini G, Canta A, Oggioni N, Rigolio R, Cossa G, et al. Experimental epothilone B neurotoxicity: results of in vitro and in vivo studies. Neurobiol Dis. 2009;35:270–7.
pubmed: 19464369
Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 2001;7:1429–37.
pubmed: 11350914
Pronzato P. New therapeutic options for chemotherapy-resistant metastatic breast cancer: the epothilones. Drugs. 2008;68:139–46.
pubmed: 18197722
Clinical trial data. for ABJ879 (Novartis) was not publicly disclosed.
Sessa C, Perotti A, Llado A, Cresta S, Capri G, Voi M, et al. Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule. Ann Oncol. 2007;18:1548–53.
pubmed: 17761711
Kaur J, Gulati M, Jha NK, Disouza J, Patravale V, Dua K, et al. Recent advances in developing polymeric micelles for treating cancer: breakthroughs and bottlenecks in their clinical translation. Drug Discov Today. 2022;27:1495–512.
pubmed: 35158056
Zhou Q, Shao S, Wang J, Xu C, Xiang J, Piao Y, et al. Enzyme-activatable polymer-drug conjugate augments tumour penetration and treatment efficacy. Nat Nanotechnol. 2019;14:799–809.
pubmed: 31263194
Sun C, Lu J, Wang J, Hao P, Li C, Qi L, et al. Redox-sensitive polymeric micelles with aggregation-induced emission for bioimaging and delivery of anticancer drugs. J Nanobiotechnol. 2021;19:1–15.
Liang X, Shi B, Wang K, Fan M, Jiao D, Ao J, et al. Development of self-assembling peptide nanovesicle with bilayers for enhanced EGFR-targeted drug and gene delivery. Biomaterials. 2016;82:194–207.
pubmed: 26763734
Ao H, Wang Z, Lu L, Ma H, Li H, Fu J, et al. Enhanced tumor accumulation and therapeutic efficacy of liposomal drugs through over-threshold dosing. J Nanobiotechnol. 2022;20:1–14.
Shen Y, Jin E, Zhang B, Murphy CJ, Sui M, Zhao J, et al. Prodrugs forming high drug loading multifunctional nanocapsules for intracellular cancer drug delivery. J Am Chem Soc. 2010;132:4259–65.
pubmed: 20218672
Pan S, Zhang Y, Natalia A, Lim CZ, Ho NR, Chowbay B, et al. Extracellular vesicle drug occupancy enables real-time monitoring of targeted cancer therapy. Nat Nanotechnol. 2021;16:734–42.
pubmed: 33686255
Wang J, Hu S, Mao W, Xiang J, Zhou Z, Liu X, et al. Assemblies of peptide-cytotoxin conjugates for tumor-homing chemotherapy. Adv Funct Mater. 2019;29:1807446.
Li F, Liang Y, Wang M, Xu X, Zhao F, Wang X, et al. Multifunctional nanoplatforms as cascade-responsive drug-delivery carriers for effective synergistic chemo-photodynamic cancer treatment. J Nanobiotechnol. 2021;19:1–18.
Smith BA, Bertozzi CR. The clinical impact of glycobiology: targeting selectins, siglecs and mammalian glycans. Nat Rev Drug Discov. 2021;20:217–43.
pubmed: 33462432
pmcid: 7812346
Moghaddam FD, Heidari G, Zare EN, Djatoubai E, Paiva-Santos AC, Bertani FR, et al. Carbohydrate polymer-based nanocomposites for breast cancer treatment. Carbohydr Polym. 2023;304:120510.
pubmed: 36641174
Silant’ ev VE, Shmelev ME, Belousov AS, Patlay AA, Shatilov RA, Farniev VM, et al. How to develop drug delivery system based on carbohydrate nanoparticles targeted to brain tumors. Polymers. 2023;15:2516.
pubmed: 37299315
Casi G, Neri D. Antibody-drug conjugates and small molecule-drug conjugates: opportunities and challenges for the development of selective anticancer cytotoxic agents. J Med Chem. 2015;58:8751–61.
pubmed: 26079148
Chen YT, Luo YX, Chan SH, Chiu WY, Yang HW. Dual antibody-aided mesoporous nanoreactor for H
Xu Y, Qian L, Fang M, Liu Y, Xu ZJ, Ge X, et al. Tumor selective self-assembled nanomicelles of carbohydrate-epothilone B conjugate for targeted chemotherapy. Eur J Med Chem. 2023;259:115693.
pubmed: 37531745
Xia X, Yang X, Huang P, Yan D. ROS-Responsive nanoparticles formed from RGD – epothilone B conjugate for targeted cancer therapy. ACS Appl Mater Interfaces. 2020;12:18301–8.
pubmed: 32242653
Nord K, Gunneriusson E, Ringdahl J, Ståhl S, Uhlén M, Nygren PÅ. Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain. Nat Biotechnol. 1997;15:772–7.
pubmed: 9255793
Orlova A, Magnusson M, Eriksson TL, Nilsson M, Larsson B, Höidén-Guthenberg I, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 2006;66:4339–48.
pubmed: 16618759
Ståhl S, Gräslund T, Karlström AE, Frejd FY, Nygren PÅ, Löfblom J. Affibody molecules in biotechnological and medical applications. Trends Biotechnol. 2017;35:691–712.
pubmed: 28514998
Luo R, Liu H, Cheng Z. Protein scaffolds: antibody alternatives for cancer diagnosis and therapy. RSC Chem Biol. 2022;3:830–47.
pubmed: 35866165
pmcid: 9257619
Gao W, Xia X, Yang X, Li Q, Xia X, Huang W, et al. Amphiphilic Affibody-PROTAC conjugate self-assembled nanoagents for targeted cancer therapy. Chem Eng J. 2024;495:153437.
Xia X, Yang X, Huang W, Xia X, Yan D. Self-assembled nanomicelles of affibody-drug conjugate with excellent therapeutic property to cure ovary and breast cancers. Nano-Micro Lett. 2022;14:33.
Yang X, Xia X, Huang W, Xia X, Yan D. Highly efficient tumor-targeted nanomedicine assembled from affibody-drug conjugate for colorectal cancer therapy. Nano Res. 2023;16:5256–64.
Chen D, Zhang G, Li R, Guan M, Wang X, Zou T, et al. Biodegradable, hydrogen peroxide, and glutathione dual responsive nanoparticles for potential programmable paclitaxel release. J Am Chem Soc. 2018;140:7373–6.
pubmed: 29799737
Hu JJ, Lei Q, Peng MY, Zheng DW, Chen YX, Zhang XZ. A positive feedback strategy for enhanced chemotherapy based on ROS-triggered self-accelerating drug release nanosystem. Biomaterials. 2017;128:136–46.
pubmed: 28325685
Wilson DS, Dalmasso G, Wang L, Sitaraman SV, Merlin D, Murthy N. Orally delivered thioketal nanoparticles loaded with TNF-α – siRNA target inflammation and inhibit gene expression in the intestines. Nat Mater. 2010;9:923–8.
pubmed: 20935658
pmcid: 3142359
Eigenbrot C, Ultsch M, Dubnovitsky A, Abrahmsén L, Härd T. Structural basis for high-affinity HER2 receptor binding by an engineered protein. Proc Natl Acad Sci USA. 2010;107:15039–44.
pubmed: 20696930
pmcid: 2930565
Altai M, Liu H, Ding H, Mitran B, Edqvist PH, Tolmachev V, et al. Affibody-derived drug conjugates: potent cytotoxic molecules for treatment of HER2 over-expressing tumors. J Control Release. 2018;288:84–95.
pubmed: 30172673
Srinivasarao M, Galliford CV, Low PS. Principles in the design of ligand-targeted cancer therapeutics and imaging agents. Nat Rev Drug Discov. 2015;14:203–19.
pubmed: 25698644
Rinaldi A, Caraffi R, Grazioli MV, Oddone N, Giardino L, Tosi G, et al. Applications of the ROS-responsive thioketal linker for the production of smart nanomedicines. Polymers. 2022;14:687.
pubmed: 35215600
pmcid: 8874672
Hoppmann S, Miao Z, Liu S, Liu H, Ren G, Bao A, et al. Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting. Bioconjug Chem. 2011;22:413–21.
pubmed: 21299201
pmcid: 3059402
Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 1991;51:794–8.
pubmed: 1846317
Sochaj-Gregorczyk AM, Serwotka-Suszczak AM, Otlewski J. A novel affibody-auristatin e conjugate with a potent and selective activity against HER2 + cell lines. J Immunother. 2016;39:223–32.
pubmed: 27227324
Serwotka-Suszczak AM, Sochaj-Gregorczyk AM, Pieczykolan J, Krowarsch D, Jelen F, Otlewski J. A conjugate based on anti-HER2 diaffibody and auristatin E targets HER2-positive cancer cells. Int J Mol Sci. 2017;18:401.
pubmed: 28216573
pmcid: 5343935
Beuttler J, Rothdiener M, Müller D, Frejd FY, Kontermann RE. Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL). Bioconjug Chem. 2009;20:1201–8.
pubmed: 19435362
Seijsing J, Lindborg M, Höidén-Guthenberg I, Bönisch H, Guneriusson E, Frejd FY, et al. An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein. Proc Natl Acad Sci USA. 2014;111:17110–5.
pubmed: 25406323
pmcid: 4260588